Open AccessIrinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer
Author(s) -
Hind Mrabti,
Christelle De La Fouchardière,
Françoise Desseigne,
Sophie Dussart,
Sylvie Négrier,
Hassan Errihani
Publication year - 2009
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.59907
Subject(s) - cetuximab , irinotecan , medicine , colorectal cancer , oxaliplatin , regimen , oncology , cancer
The aim of the present study was to compare the efficacy and safety of weekly versus an every 2-week administration of cetuximab in association with irinotecan in patients with metastatic colorectal cancer (MCRC).